Peptide inhibitors of toxins derived from LL-37
View Patent ↗The invention relates to a peptidic compound with affinity to bacterial and fungal toxins, especially to lipopolysaccharide or lipoteichoic acid. The peptidic compound includes an amino acid sequence X 1 KEFX 2 RIVX 3 RIKX 4 FLRX 5 LVX 6 , wherein X 1 represents the N-terminal part: X 2 is K or E; X 3 is Q or E; X 4 is D or R; X 5 is N or E; X 6 represents the C-terminal part: an amino acid of the core sequence is optionally derivatized; the N-terminal part is acetylated, and/or the C-terminal part is amidated, and/or the sequence differs from the native amino acid sequence X 1 KEFKRIVQRIKDFLRNLVX 6 .
1. A peptidic compound with affinity to bacterial and fungal toxins, and especially to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) comprising the amino acid sequence IGKEFKRIVERIKRFLRELVRPLR (SEQ ID NO: 5), wherein one or more of the amino acids of the sequence are optionally derivatized, wherein the N-terminal part is acetylated and/or the C-terminal part is amidated.
2. The compound according to claim 1 , wherein the N-terminus is acetylated.
3. The compound according to claim 1 , wherein the C-terminus is amidated.
4. The compound according to claim 1 , wherein the N-terminus is acetylated and the C-terminus is amidated.
5. A pharmaceutical composition, comprising the compound according to claim 1 , and one or more pharmaceutically acceptable carriers or excipients.
6. The pharmaceutical composition according to claim 5 , being formulated, processed, and adapted for parenteral administration, preferably for intravascular, intramuscular, subcutaneous, or intralesional injection.
7. The pharmaceutical composition according to claim 5 , being formulated, processed, and adapted for the local administration to the mucosa of an affected region or tissue, such as in form of an irrigation liquid, ear drops, nose drops, an aerosol, a powder aerosol, a liquid for nebulization, a gel, a suspension, or a mucoadhesive dosage form.
8. The pharmaceutical composition according to claim 5 , further comprising a drug targeting agent, a bioavailability enhancing agent, and/or a controlled delivery agent.
9. A method of treating a fungal or bacterial infection induced by lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in a human in need thereof, said method comprising administering to a mammal an effective amount of a peptidic compound with affinity to bacterial and fungal toxins, and especially to lipopolysaccharide (LPS) or lipoteichoic acid (LTA), which comprises the amino acid sequence set forth in SEQ ID NO: 5, wherein one or more of the amino acids of the sequence are optionally derivatized; wherein the N-terminal part is acetylated and/or the C-terminal part is amidated.
10. The method according to claim 9 , wherein said infection is a middle ear infection, upper respiratory infection, acute sinusitis, chronic sinusitis, acute otitis, chronic otitis, and/or otitis media.
11. A method of treating an infection in a human in need thereof, said method comprising administering to a mammal an effective amount of a peptidic compound with affinity to bacterial and fungal toxins, and especially to lipopolysaccharide (LPS) or lipoteichoic acid (LTA), which comprises the amino acid sequence set forth in SEQ ID NO: 5, wherein one or more of the amino acids of the sequence are optionally derivatized, wherein the N-terminal part is acetylated and/or the C-terminal part is amidated; wherein said infection is selected from the group consisting of a middle ear infection, upper respiratory infection, acute sinusitis, chronic sinusitis, acute otitis, chronic otitis, and/or otitis media with effusion.